Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020756 | Journal of Neuroimmunology | 2013 | 10 Pages |
Abstract
We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12 months. IL-17 levels were significantly higher at Month 6 (p = 0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p = 0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8 + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, Kouichi Ito, Payal Patel, Mark Rametta,